A targeted delivery system was created by the adsorption of aptamer against epithelial cell adhesion molecule (EPCAM), a marker of HCC stem cells, and PAMAM onto hollow mesoporous silica nanoparticles (HMSN) for the co-delivery of sorafenib and CRISPR/Cas9 system targeting EGFR. The gene discussed is EPCAM; the disease is hepatocellular carcinoma.